Itsas-bakterioak: isolamendua, karakterizazioa eta interes bioteknologikoa duten entzimen produkzio-gaitasuna

Lan honetan Ekialdeko Kantauri itsasoko itsas-bakterioak isolatu, karakterizatu eta interes bioteknologikoa duten aktibitate entzimatikoen produkzio-gaitasuna analizatu da. Amilasa, zelulasa, kaseinasa, DNAsa eta fosfatasa entzimen aktibitateak detektatu dira, hain zuzen ere

Modulation of intestinal barrier function by glucocorticoids: Lessons from preclinical models

This work was supported by the "Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd)", belonging to Instituto de Salud Carlos III, Spain, and grants from: Ministry of Economy and Competitivity, partly with Fondo Europeo de Desarrollo Regional FEDER funds [SAF2017-88457-R, AGL2017-85270-R]; "Junta de Andalucia", Spain [CTS235, CTS164]; "Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III", Spain (PI19/00819), co-funded by European Regional Development Fund/European Social Fund, "Investing in your future"; "Junta de Castilla y Leon" (SA074P20),Spain; "Fundacio Marato TV3'' (201916-31), Spain; AECC Scientific Foundation (2017/2020), Spain; and "Centro Internacional sobre el Envejecimiento" (OLD-HEPAMARKER, 0348_CIE_6_E), Spain. MAA and MTG were supported by fellowships from the Ministry of Education. MA was supported by a postdoctoral contract with the CIBERehd. Funding for open access charge: Universidad de Granada/CBUA.Glucocorticoids (GCs) are widely used drugs for their anti-inflammatory and immunosuppressant effects, but they are associated with multiple adverse effects. Despite their frequent oral administration, relatively little attention has been paid to the effects of GCs on intestinal barrier function. In this review, we present a summary of the published studies on this matter carried out in animal models and cultured cells. In cultured intestinal epithelial cells, GCs have variable effects in basal conditions and generally enhance barrier function in the presence of inflammatory cytokines such as tumor necrosis factor (TNF). In turn, in rodents and other animals, GCs have been shown to weaken barrier function, with increased permeability and lower production of IgA, which may account for some features observed in stress models. When given to animals with experimental colitis, barrier function may be debilitated or strengthened, despite a positive anti-inflammatory activity. In sepsis models, GCs have a barrier-enhancing effect. These effects are probably related to the inhibition of epithelial cell proliferation and wound healing, modulation of the microbiota and mucus production, and interference with the mucosal immune system. The available information on underlying mechanisms is described and discussed."Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, SpainMinistry of Economy and CompetitivityEuropean Commission SAF2017-88457-R AGL2017-85270-RJunta de Andalucia European Commission CTS235 CTS164Instituto de Salud Carlos III PI19/00819European Regional Development Fund/European Social Fund, "Investing in your future"Junta de Castilla y Leon SA074P20Fundacio Marato TV3, Spain 201916-31AECC Scientific Foundation, Spain"Centro Internacional sobre el Envejecimiento" (OLD-HEPAMARKER), Spain 0348_CIE_6_EMinistry of EducationCIBERehdUniversidad de Granada/CBU

Glucocorticoid receptor intestinal epithelial knockout mice show attenuated colonic inflammatory response but unaffected permeability in early experimental sepsis

Introduction: Sepsis is defined as an organic dysfunction that threatens the life of patients due to an abnormally regulated response to infection [1]. The initial phase of sepsis is dominated by an increased production of proinflammatory cytokines, which leads to augmented capillary permeability, extravasation, hypercoagulability and myelopoiesis. One of the main sources of infection in sepsis is believed to be the intestinal microbiota via traslocation through the mucosa to the bloodstream. Systemic inflammation weakens intestinal barrier function (IBF) in animal models, resulting in increased bacterial traslocation [2]. Even if the management of sepsis has advanced in the last decades, mortality is still high and there are blanks in terms of pathological systems and long-term consequences. Thus, the search for effective treatments is clearly justified. Glucocorticoids (GC) are part of the drugs used in sepsis, but they have only shown a moderate therapeutic effect. This fact may be caused by harmful effects of GCs on IBF, whose compromise may limit GC clinical benefit by facilitating luminal translocation of microorganisms. Besides, GC treatment impairs epithelial healing in experimental colitis in mice [3]. Previous results of our research group have shown that mice with induced deletion of the GC receptor (GR) in intestinal epithelial cells (i.e. NR3C1ΔIEC mice) are protected against dextran sulphate sodium (DSS)-induced colitis [4]. In turn, gene deletion results in a short lived inflammatory response in the colon [5]. Objective: Understanding the role of the intestinal epithelial GR and its involvement in IBF regulation in experimental sepsis, with the ultimate goal of improving the management of sepsis with GCs. Matherial and methods: The cecal ligation and puncture (CLP) model of sepsis was applied to WT C57BL/6J and NR3C1ΔIEC mice. Ceacum-exposed mice were used as control (Sham). Mice were sacrificed 24 hours after surgery. Four hours before sacrifice, mice were administered 4 kD FITC-dextran, a fluorescent marker of permeability. Colon, jejunum, adrenes, kidney and liver RT-qPCRs were performed as well as determination of plasma FITC-dextran and corticosterone plasma levels. Results: After 24 h, CLP mice exhibited elevated corticosterone plasma levels with hypoglycemia and splenomegaly. Intestinal barrier function was weakened, as indicated by increased FITC-dextran plasma levels. A modest increase in inflammatory markers (S100a8, Cxcl1) was noted in the colon and jejunum. The expression of Tjp1, involved in barrier function, was downregulated in CLP mice. Similarly, the colonic expression of Cyp11a1 and Lrh1, involved in local steroidogenesis, was lower in CLP mice, regardless of genotype. Markers of inflammation were also augmented in the lung and kidney. CLP mice exhibited hypercorticosteronemia, which was associated to increased Cyp11a1 in the adrenes. Of note, both parameters were less pronounced in KO mice. The latter also exhibited dampened inflammatory response in the colon but not the jejunum. FITC-dextran plasma levels were similarly increased in WT and KO mice. Conclusions: In the early stages of the CLP model of sepsis the colon and jejunum are inflamed, and epithelial deletion of the glucocorticoid receptor appears to modulate inflammation in the former, with no change in barrier function. Further studies will characterize the microbiota composition and phenotype in later stages and in the response to glucocorticoid treatment

Full Transcriptomic Response of Pseudomonas aeruginosa to an Inulin-Derived Fructooligosaccharide

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb. 2020.00202/full#supplementary-materialPseudomonas aeruginosa is an ubiquitous gram-negative opportunistic human pathogen which is not considered part of the human commensal gut microbiota. However, depletion of the intestinal microbiota (Dysbiosis) following antibiotic treatment facilitates the colonization of the intestinal tract by Multidrug-Resistant P. aeruginosa. One possible strategy is based on the use of functional foods with prebiotic activity. The bifidogenic effect of the prebiotic inulin and its hydrolyzed form (fructooligosaccharide: FOS) is well established since they promote the growth of specific beneficial (probiotic) gut bacteria such as bifidobacteria. Previous studies of the opportunistic nosocomial pathogen Pseudomonas aeruginosa PAO1 have shown that inulin and to a greater extent FOS reduce growth and biofilm formation, which was found to be due to a decrease in motility and exotoxin secretion. However, the transcriptional basis for these phenotypic alterations remains unclear. To address this question we conducted RNAsequence analysis. Changes in the transcript level induced by inulin and FOS were similar, but a set of transcript levels were increased in response to inulin and reduced in the presence of FOS. In the presence of inulin or FOS, 260 and 217 transcript levels, respectively, were altered compared to the control to which no polysaccharide was added. Importantly, changes in transcript levels of 57 and 83 genes were found to be specific for either inulin or FOS, respectively, indicating that both compounds trigger different changes. Gene pathway analyses of differentially expressed genes (DEG) revealed a specific FOS-mediated reduction in transcript levels of genes that participate in several canonical pathways involved in metabolism and growth, motility, biofilm formation, b-lactamase resistance, and in the modulation of type III and VI secretion systems; results that have been partially verified by real time quantitative PCR measurements. Moreover, we have identified a genomic island formed by a cluster of 15 genes, encoding uncharacterized proteins, which were repressed in the presence of FOS. The analysis of isogenic mutants has shown that genes of this genomic island encode proteins involved in growth, biofilm formation and motility. These results indicate that FOS selectively modulates bacterial pathogenicity by interfering with different signaling pathways.This work was supported by grants from the Spanish Ministry for Economy and Competitiveness (AGL2017-85270-R). CS is funded by the program Juan de la Cierva-Formación (FJCI-2015-23810)

Papel de la enzima fosfatasa alcalina no específica de tejido (TNAP) en el epitelio intestinal en la inflamación

Introducción: la fosfatasa alcalina (AP) es una familia de enzimas que ha sido relacionada con la protección frente a inflamación intestinal. Se ha descrito que una de sus isoformas, la fosfatasa alcalina intestinal (IAP), es capaz de desfosforilar diferentes antígenos bacterianos, de tal forma que la enzima regula el crecimiento de la microbiota e impide el paso de antígenos activos. En cuanto a la isoforma TNAP, se ha observado que su expresión se encuentra incrementada en la colitis experimental, no solo debido a la infiltración de células del sistema inmunológico, sino también por el incremento de expresión de esta enzima en las células del epitelio intestinal. Objetivo: conocer el papel de la TNAP en la inflamación intestinal. Métodos y resultados: se ha generado un modelo de ratón con deleción condicional inducible del gen que codifica TNAP (Alpl) en el epitelio intestinal (ratones AlplIEC-/-). El silenciamiento específico de TNAP en IECs en inflamación por DSS (7 días) supuso una pérdida mayor de peso en los ratones, sin observarse diferencias en el índice de actividad de la enfermedad (DAI). A nivel histológico se observó un mayor nivel de infiltración en la submucosa en el colon de los ratones sin TNAP. Los ratones AlplIEC-/- presentaron una expresión reducida de marcadores inflamatorios en el colon, como S100a8, Il6 y Tnf. Por el contrario, la deficiencia en TNAP en el epitelio intestinal supuso un aumento en la expresión de la fosfatasa alcalina intestinal global (Akp6) en el colon, sugiriendo que podría existir algún mecanismo de compensación. Además, la ausencia de TNAP en el epitelio intestinal provocó un aumento de expresión de genes relacionados en el mantenimiento de la función de barreara, como Muc4, Tjp1 y Tff3. Conclusión: los ratones AlplIEC-/- presentan un fenotipo mixto, con mayor infiltración y daño histológico pero menor expresión de marcadores inflamatorios en la colitis por DSS. Perspectivas futuras: se realizarán estudios de transcriptómica para conocer el efecto de la TNAP presente en el intestino sobre la función de barrera intestinal y sobre la microbiota

A Standardized Extract of Lentinula edodes Cultured Mycelium Inhibits Pseudomonas aeruginosa Infectivity Mechanisms

This work was supported by grants from FEDER project of Junta de Andalucia, Spain (30B572F301), Ministry of Economy and Competitivity, partly with Fondo Europeo de Desarrollo Regional FEDER funds (SAF2017-88457-R and AGL2017-85270-R), and by Junta de Andalucia (CTS235 and CTS164). MT-G was supported by the University of the Ministry of Education (Spain). CIBERehd is funded by Instituto de Salud Carlos III.The priority pathogen list of the World Health Organization classified Pseudomonas aeruginosa as the second top critical pathogen. Hence, the development of novel antibacterial strategies to tackle this bacterium is highly necessary. Herein we explore the potential antibacterial effect of a standardized extract of cultured mycelium of Lentinula edodes (AHCCR ) on P. aeruginosa. AHCCR was found to inhibit the growth rate and biofilm formation of strain PAO1. No change in swarming was observed, but AHCCR hampered swimming and twitching motility. In accordance, a decreased expression of metabolism, growth, and biofilm formation genes was shown. AHCCR also diminished the levels of exotoxin A and bacteria inside IEC18 cells and the secretion of IL-6, IL-10 and TNF by infected macrophages. This effect was related to a reduced phosphorylation of MAPKs and to bacteria internalization. Taken together, our data suggest that AHCCR has a potential role to prevent P. aeruginosa infections and may lead to the development of new therapies.FEDER project of Junta de Andalucia, Spain 30B572F301Ministry of Economy and CompetitivityEuropean Commission SAF2017-88457-R AGL2017-85270-RUniversity of the Ministry of Education (Spain)Junta de Andalucia CTS235 CTS164Instituto de Salud Carlos III European Commissio

Deficiency in Tissue Non-Specific Alkaline Phosphatase Leads to Steatohepatitis in Mice Fed a High Fat Diet Similar to That Produced by a Methionine and Choline Deficient Diet

Funding: This research was funded by the Ministry of Economy and Competitivity of Spain, partly with Fondo Europeo de Desarrollo Regional FEDER funds [BFU2014-57736-P, AGL2014-58883-R, SAF2017-88457-R, AGL2017-85270-R] and by Junta de Andalucía [CTS235, CTS164]. MTG, RGB and CHC were supported by fellowships from the Ministry of Education. CIBERehd is funded by Instituto de Salud Carlos III. Institutional Review Board Statement: The study was conducted according to the guidelines of the Guide for the Care and Use of Laboratory Animals, and approved by the Animal Welfare Committee of the University of Granada (registry number: CEEA 01/03/2017–029). Informed Consent Statement: Not applicable for studies not involving humans. Acknowledgments: We gratefully acknowledge the assistance of Mercedes González and the rest of the group.The liver expresses tissue-nonspecific alkaline phosphatase (TNAP), which may participate in the defense against bacterial components, in cell regulation as part of the purinome or in bile secretion, among other roles. We aimed to study the role of TNAP in the development of hepatosteatosis. TNAP+/− haplodeficient and wild type (WT) mice were fed a control diet (containing 10% fat w/w) or the same diet deficient in methionine and choline (MCD diet). The MCD diet induced substantial weight loss together with hepatic steatosis and increased alanine aminotransferase (ALT) plasma levels, but no differences in IL-6, TNF, insulin or resistin. There were no substantial differences between TNAP+/− and WT mice fed the MCD diet. In turn, TNAP+/− mice receiving the control diet presented hepatic steatosis with alterations in metabolic parameters very similar to those induced by the MCD diet. Nevertheless, no weight loss, increased ALT plasma levels or hypoglycemia were observed. These mice also presented increased levels of liver TNF and systemic resistin and glucagon compared to WT mice. The phenotype of TNAP+/− mice fed a standard diet was normal. In conclusion, TNAP haplodeficiency induces steatosis comparable to that produced by a MCD diet when fed a control diet.Ministry of Economy and Competitivity of SpainEuropean Commission BFU2014-57736-P AGL2014-58883-R SAF2017-88457-R AGL2017-85270-RJunta de Andalucia CTS235 CTS164Ministry of EducationInstituto de Salud Carlos III European Commissio

Fosfatasa alcalina no específica de tejido. Estudio de propiedades funcionales sobre la función de barrera intestinal y en la inflamación

Tesis Univ. Granada

Itsas-bakterioak: isolamendua, karakterizazioa eta interes bioteknologikoa duten entzimen produkzio-gaitasuna

Lan honetan Ekialdeko Kantauri itsasoko itsas-bakterioak isolatu, karakterizatu eta interes bioteknologikoa duten aktibitate entzimatikoen produkzio-gaitasuna analizatu da. Amilasa, zelulasa, kaseinasa, DNAsa eta fosfatasa entzimen aktibitateak detektatu dira, hain zuzen ere

Evidence for shared genetic risk factors between lymphangioleiomyomatosis and pulmonary function

This research was supported by Asociacion Espanola de LAM; The LAM Foundation Seed Grant 2019; Carlos III Institute of Health grants PI18/01029, PI21/01306 and ICI19/00047 (co-funded by European Regional Development Fund (ERDF), "A way to build Europe"); Ministry of Economy and Competitivity grant SAF2017-88457-R; the Generalitat de Catalunya SGR 2017-449 and 2017-529; PERIS PFI-Salut SLT017-20-000076; and the CERCA Program to IDIBELL and Institut Germans Trias i Pujol. X. Farre is supported by the VEIS project (001-P-001647, ERDF Operational Programme of Catalonia 2014-2020; co-funded by ERDF, "A way to build Europe"). Funding information for this article has been deposited with the Crossref Funder Registry.Introduction Lymphangioleiomyomatosis (LAM) is a rare low-grade metastasising disease characterised by cystic lung destruction. The genetic basis of LAM remains incompletely determined, and the disease cell-of-origin is uncertain. We analysed the possibility of a shared genetic basis between LAM and cancer, and LAM and pulmonary function. Methods The results of genome-wide association studies of LAM, 17 cancer types and spirometry measures (forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), FEV1/FVC ratio and peak expiratory flow (PEF)) were analysed for genetic correlations, shared genetic variants and causality. Genomic and transcriptomic data were examined, and immunodetection assays were performed to evaluate pleiotropic genes. Results There were no significant overall genetic correlations between LAM and cancer, but LAM correlated negatively with FVC and PEF, and a trend in the same direction was observed for FEV1. 22 shared genetic variants were uncovered between LAM and pulmonary function, while seven shared variants were identified between LAM and cancer. The LAM-pulmonary function shared genetics identified four pleiotropic genes previously recognised in LAM single-cell transcriptomes: ADAM12, BNC2, NR2F2 and SP5. We had previously associated NR2F2 variants with LAM, and we identified its functional partner NR3C1 as another pleotropic factor. NR3C1 expression was confirmed in LAM lung lesions. Another candidate pleiotropic factor, CNTN2, was found more abundant in plasma of LAM patients than that of healthy women. Conclusions This study suggests the existence of a common genetic aetiology between LAM and pulmonary function.Asociacion Espanola de LAMLAM Foundation Seed Grant 2019Instituto de Salud Carlos III PI18/01029 PI21/01306 ICI19/00047European Regional Development Fund (ERDF), "A way to build Europe"Ministry of Economy and Competitivity SAF2017-88457-RGeneralitat de CatalunyaGeneral Electric SGR 2017-449 2017-529PERIS PFI-Salut SLT017-20-000076CERCA ProgramVEIS project 001-P-001647ERDF, "A way to build Europe" ERDF Operational Programme of Catalonia 2014-202